TBC 609

Drug Profile

TBC 609

Alternative Names: TBC609

Latest Information Update: 05 Feb 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Encysive Pharmaceuticals
  • Class Antirheumatics; Peptides; Vascular disorder therapies
  • Mechanism of Action Vascular cell adhesion molecule inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Atherosclerosis; Ischaemic heart disorders; Multiple sclerosis; Rheumatoid arthritis

Most Recent Events

  • 20 Jul 1998 No-Development-Reported for Atherosclerosis in USA (Unknown route)
  • 20 Jul 1998 No-Development-Reported for Ischaemic heart disorders in USA (Unknown route)
  • 20 Jul 1998 No-Development-Reported for Multiple sclerosis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top